Fabio Zattoni
Overview
Explore the profile of Fabio Zattoni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
134
Citations
1015
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Matrone F, Urso L, Girometti R, Polesel J, Sepulcri M, Pierantoni F, et al.
Ther Adv Urol
. 2025 Mar;
17:17562872251321971.
PMID: 40083770
Background: Next-generation imaging (NGI) technologies such as multiparametric magnetic resonance imaging (mpMRI) and total-body NGI (tbNGI) methodologies including choline, fluciclovine or PSMA positron emission tomography/computed tomography (PET/CT), whole-body MRI (wbMRI),...
2.
Zattoni F, Novara G, Dal Moro F, Tandogdu Z
Eur Urol Focus
. 2025 Mar;
PMID: 40037974
Transperineal prostate biopsy offers advantages over transrectal biopsy in terms of cancer detection in specific prostate areas, potential use of larger-gauge needles for tissue sampling, a lower risk of severe...
3.
Zattoni F, Novara G, Dal Moro F, Tandogdu Z
Eur Urol Focus
. 2025 Mar;
PMID: 40037972
Transperineal prostate biopsy offers advantages over transrectal biopsy in terms of cancer detection in specific prostate areas, potential use of larger-gauge needles for tissue sampling, a lower risk of severe...
4.
Contieri R, Guigui A, Gondran-Tellier B, Basile G, Zattoni F, Gallioli A, et al.
Int Urol Nephrol
. 2025 Feb;
PMID: 39934553
Introduction: To evaluate whether adherence to specific quality criteria in the management of T1 non-muscle-invasive bladder cancer (NMIBC) undergoing second-look transurethral resection of bladder tumor (TURBT) leads to improved oncological...
5.
Marra G, Barletta F, Scuderi S, Montefusco G, Olivier J, Affentranger A, et al.
J Urol
. 2025 Feb;
:101097JU0000000000004468.
PMID: 39929079
Purpose: To assess the survival outcomes of adjuvant radiation therapy (aRT) vs observation with or without early salvage RT (Obs ± esRT) for cN0M0 pN1 prostate cancer (PCa) and to...
6.
Gandaglia G, Barletta F, Scuderi S, Scilipoti P, Rajwa P, Huebner N, et al.
Eur Urol Oncol
. 2025 Jan;
PMID: 39890547
Background And Objective: Extended pelvic lymph node dissection (ePLND) is recommended in selected radical prostatectomy (RP) prostate cancer (PCa) patients for staging purposes. We aim to externally validate available tools...
7.
Zattoni F, Carletti F, Reitano G, Novara G, Dal Moro F
Minerva Urol Nephrol
. 2025 Jan;
76(6):785-787.
PMID: 39831859
No abstract available.
8.
9.
Soeterik T, Heetman J, Hermsen R, Wever L, Lavalaye J, Vinken M, et al.
Eur Urol Oncol
. 2024 Nov;
PMID: 39613565
Background And Objective: The role of prostate-specific membrane antigen (PSMA)-based positron emission tomography (PET)/computed tomography (CT) in addition to magnetic resonance imaging (MRI) for local staging of prostate cancer (PC)...
10.
Giannini G, Kafka M, Neuwirt H, Artamonova N, di Santo G, Virgolini I, et al.
Clin Genitourin Cancer
. 2024 Nov;
23(1):102260.
PMID: 39608079
Background: Lu PSMA therapy is increasingly used for metastatic castration-resistant prostate cancer (mCRPC) treatment. However, data on its efficacy and safety in patients previously treated with Ra remain limited. Methods:...